GlassScriptPhysician profile
Michael A Goodman
NPI 1013229814
$20,089.28
in general payments reported to CMS, 2019-2025
40 companies · $4,089 in 2025
The $4,089 reported for 2025 was more than what 81% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $261 · 2020: $1,989 · 2021: $2,507 · 2022: $3,032 · 2023: $3,320 · 2024: $4,891 · 2025: $4,089.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Consulting Fee: $1,387 · Education: $362.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,550.18 |
| Consulting Fee | $1,387.47 |
| Education | $362.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $4,279.00 | 2020-2025 | |
| Astrazeneca Pharmaceuticals LP | $3,006.78 | 2020-2025 | Tezspire, Fasenra, Airsupra |
| Csl Behring | $2,464.33 | 2020-2025 | Hizentra, Haegarda, Andembry |
| Regeneron Healthcare Solutions, INC. | $1,303.02 | 2019-2025 | Dupixent |
| Glaxosmithkline, LLC. | $1,252.80 | 2020-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Grifols USA, LLC | $1,015.29 | 2019-2025 | Xembify, Prolastin-C Liquid |
| Novartis Pharmaceuticals Corporation | $670.49 | 2020-2025 | |
| Pfizer INC. | $642.39 | 2020-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $550.04 | 2020-2025 | Eohilia, Cuvitru, Takhzyro |
| Alk-Abello, INC | $518.98 | 2020-2023 | Odactra, Ragwitek, Grastek |
| Amgen INC. | $508.89 | 2021-2025 | Tezspire, Actimmune, Uplizna |
| Octapharma USA, INC. | $437.32 | 2021-2025 | Panzyga, Cutaquig, Octagam Immune Globulin (Human) |
| Optinose US, INC. | $383.63 | 2020-2025 | |
| Genentech USA, INC. | $381.81 | 2020-2025 | Xolair |
| Sanofi-Aventis U.S. LLC | $369.87 | 2020-2025 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Goodman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.